- UM 191
- StemRegenin 1 (SR1)
SW03329115-PGDH enzyme inhibitor |
Sample solution is provided at 25 µL, 10mM.
Quality Control & MSDS
- View current batch:
- Purity = 98.02%
- COA (Certificate Of Analysis)
- HPLC(Retest)
- NMR (Nuclear Magnetic Resonance)
- MSDS (Material Safety Data Sheet)
- Datasheet
Chemical structure
Kinase experiment [1]: | |
Activity assays of recombinant 15-PGDH protein | For initial characterization of inhibition of 15-PGDH enzyme activity by SW033291, reactions were assembled with experiment specific concentrations of 15-PGDH enzyme, and experiment specific concentrations of SW033291, plus 150 μM NAD(+) and 25 μM PGE2 in reaction buffer (50 mM Tris-HCl, pH7.5, 0.01% Tween 20). The reaction mix was incubated for 15 mins at 25°C in an Envision Reader. Enzyme activity was determined by following generation of NADH as assayed by recording fluorescence at Ex/Em = 340 nM/485 nM every 30s for 3 mins, commencing immediately after addition of PGE2. IC50 values were calculated with GraphPad Prism 5 software using the sigmoidal dose-response function and plotted against SW033291 concentration. |
Cell experiment [1]: | |
Cell lines | CD45- bone marrow cells |
Preparation method | The solubility of this compound in DMSO is > 20.7mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 °C for several months. |
Reacting condition | 0.5 μM; 2 hrs |
Applications | In CD45- bone marrow cells, SW033291 inhibited 15-PGDH, increased tissue levels of PGE2, and induced CXCL12 and SCF expression, which in turn accelerated homing of transplanted hematopoietic stem cells, generation of mature blood elements, as well as posttransplant recovery of normal blood counts. In addition, inhibiting 15-PGDH also stimulated cell proliferation after injury to colon or liver, and accelerated repair of these tissues. |
Animal experiment [1]: | |
Animal models | Mice receiving a bone marrow transplant and mouse models of colon and liver injury |
Dosage form | 10 mg/kg; i.p.; b.i.d. |
Applications | In mice receiving a bone marrow transplant, SW033291 promoted hematopoietic recovery. In mouse models of colon and liver injury, SW033291 lowered the levels of colitis-associated inflammatory cytokines, protected mice from colitis, as well as facilitated liver regeneration. |
Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
References: [1]. Zhang Y, Desai A, Yang SY et al. Inhibition of the prostaglandin-degrading enzyme 15-PGDH potentiates tissue regeneration. Science. 2015 Jun 12;348(6240). pii: aaa2340. |
SW033291 Dilution Calculator
calculate
SW033291 Molarity Calculator
calculate
Cas No. | 459147-39-8 | SDF | Download SDF |
Synonyms | N/A | ||
Chemical Name | 2-(butylsulfinyl)-4-phenyl-6-(thiophen-2-yl)thieno[2,3-b]pyridin-3-amine | ||
Canonical SMILES | NC1=C(S(CCCC)=O)SC2=NC(C3=CC=CS3)=CC(C4=CC=CC=C4)=C21 | ||
Formula | C21H20N2OS3 | M.Wt | 412.59 |
Solubility | ≥20.65mg/mL in DMSO | Storage | Store at -20°C |
Physical Appearance | A solid | Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. |
SW033291 is a potent inhibitor of 15-PGDH enzyme with IC50 value of 1.5 nM and dissociation constant Ki app value of 0.1 nM. SW033291 inhibits 15-PGDH with noncompetitive pattern. SW033291 shifted the 15-PGDH melting temperature by 13.5°C. [1]Treatment of A549 cells with SW033291 increased PGE2 levels by 3.5-fold at 500 nM, with EC50 value of ~75 nM. In CD45 cells, SW033291 treatment induced a greater than four-fold increase in expression of CXCL12 and SCF. In SKL cells, SW033291 had no significant effects on expression of CXCL12, SCF, CXCR4, survivin, or JAG1. SW033291 also increased cyclic AMP levels in CD45 cells. SW033291 treatment increases the expression of cytokines from the hematopoietic niche. [1]The phenotype of mice injected with SW033291 closely matched with 15-PGDH knockout mice (10mg/kg). SW033291 induced a two-fold increase in PGE2 levels in bone marrow, colon, lung, and liver. Importantly, no toxicity was induced by injecting SW033291 for inhibition of 15-PGDH in adult mice. Mice injected with SW033291 exhibited many good benefits, such as doubling peripheral neutrophils, a 65% increase in marrow SKL cells, a 71% increase in marrow SLAM cells, and 55% increases in the numbers of hematopoietic colonies. [1]Reference:1. Zhang Y, Desai A, Yang SY et al. Inhibition of the prostaglandin-degrading enzyme 15-PGDH potentiates tissue regeneration. Science. 2015 Jun 12;348(6240). pii: aaa2340.
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
DNA拓扑异构酶Ⅱ与抗肿瘤药物靶点的研究进展.doc(59.5k)
请规范发贴,求助贴请在标题前加【求助】,谢谢您的合作。——by草根
1970科家致癌RNA病毒发现种特殊RNA病毒聚合酶,该酶能RNA模板,根据碱基互补原则.程与般病毒转录向相反,故称逆转录,催化程酶称逆转录酶,发现哺乳物胚胎细胞裂淋巴细胞含.
逆转录病毒称携带逆转录酶病毒,先侵入宿主细胞病毒RNA模板,靠酶形DNA环化,合宿主细胞染色体原病毒形式宿主细胞代代传.
HIV(艾滋病病毒)典型逆转录病毒
伊立替康是喜树碱的半合成衍生物。喜树碱可特异性地与拓扑异构酶I结合,后者诱导可逆性单链断裂,从而使DNA双链结构解旋;伊立替康及其活性代谢物SN-38可与拓扑异构酶I-DNA复合物结合,从而阻止断裂单链的再连接。现有研究提示,伊立替康的细胞毒作用归因于DNA合成过程中,复制酶与拓扑异构酶I-DNA一伊立替康(或SN-38)三联复合物相互作用,从而引起DNA双链断裂。哺乳动物细胞不能有效地修复这种DNA双链断裂。
毒理研究
遗传毒性:伊立替康和SN-38在Ames试验中均未显示出致突变性。伊立替康在CHO细胞染色体畸变试验和小鼠微核试验中显示了致断裂作用。
生殖毒性:在啮齿动物多次给药试验中,可见雄性动物生殖器官萎缩。雌性大鼠静脉注射14C一伊立替康,其放射性可透过胎盘屏障,大鼠和家兔试验中,可见本品对胚胎和胎儿的毒性反应。大鼠静脉注射放射性标记的伊立替康后5分钟内,可在其乳汁中检测到放射性,给药4小时后乳汁中药物浓度可达到血药浓度的65倍;雌性大鼠在围产期静脉注射本品可引起仔鼠学习能力和雌鼠仔鼠体重的下降。
尚无足够的和严格控制的孕妇临床研究资料,若患者在孕期使用本品或在使用本品期间怀孕,应被告之对胎儿的潜在危害。有生育可能的妇女在本品给药期间应避免怀孕;母亲在接受本品治疗期间应停止哺乳。
致癌性:尚未进行伊立替康长期给药的致癌性研究,但进行了大鼠连续三周、每周一次静脉注射伊立替康2mg/kg和25mg/kg,然后恢复91周的试验(大鼠静脉注射伊立替康25mg/kg后,其Cmax和AUC分别约相当于人每周给药125mg/m2后的7倍和1.3倍),结果显示,子宫喇叭口处子宫内膜间质息肉和子宫内膜间质肉瘤发生率的增加有明显的剂量依赖性。
【药代动力学】
文献报导,人体静脉注射本品后,伊立替康的血浆浓度呈常指数消除。平均消除半衰期为6~12小时,活性代谢产物SN-3 8的消除半衰期为10~20小时。因为其内酯和羟基酸是化学平衡的,故活性内酯和SN-38的半衰期与完整的伊立替康和SN-38的半衰期相近。
在50~350mg/m2的剂量范围内,伊立替康吸收面积(AUC)与剂量呈线性递增关系:SN-38的AUC增加要小于剂量的增加。在90分钟内静脉滴注本品后1小时内,活性代谢产物SN-38达到最大浓度。伊立替康与血浆蛋白的结合率为 30%~68%,明显低于SN-38与血浆蛋白的结合率(大约95%)。伊立替康主要在肝内由羧酸酯酶转化为活性代谢产物SN-38,后者代谢为葡萄糖甙酸,活性为SN-38的1/50~1/100(由体内细胞毒性检测)。体内分布不明;药物及代谢产物经尿排泄:伊立替康为11%~20%,SN-38<1%,SN-38糖甙约3%。给药48小时后胆汁蓄积和经尿排泄的药25%~50%。
【贮 藏】
遮光,密闭保存。
【包 装】
西林瓶装,1瓶/盒,有40mg及100mg两种规格。
效 期】
24个月
【执行标准】
WS1-(X-166)-2005Z
【生产企业】
企业名称:辉瑞制药;安万特制药;齐鲁制药;江苏恒瑞医药股份有限公司向左转|向右转
暂无品牌问答